Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cryoport, Inc. (NASDAQ: CYRX) has announced it will release its financial results for the first quarter ending March 31, 2023, on May 4, 2023, after U.S. market close. Alongside the earnings, a detailed review titled 'Cryoport First Quarter 2023 in Review' will be provided at 4:05 PM ET that day. The company will host a conference call at 5:00 PM ET to discuss the results, with a live webcast available on its investor relations page. The call requires a confirmation code for access and will be recorded for later replay. Cryoport specializes in temperature-controlled supply chain solutions for life sciences, with a global reach across Americas, EMEA, and APAC regions.